A Phase III Randomized, Multicenter Study Comparing Irinotecan and Cisplatin (IP) with Amrubicin and Cisplatin (AP) for the Treatment of Extensive-Stage Small-Cell Lung Cancer: (JCOG0509)

Trial Profile

A Phase III Randomized, Multicenter Study Comparing Irinotecan and Cisplatin (IP) with Amrubicin and Cisplatin (AP) for the Treatment of Extensive-Stage Small-Cell Lung Cancer: (JCOG0509)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Amrubicin (Primary) ; Cisplatin; Irinotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Mar 2014 Results published in the Journal of Clinical Oncology.
    • 18 Jun 2012 Status changed from active, no longer recruiting to discontinued.
    • 05 Jun 2012 Second interim analysis presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top